drugset / Trial / NCT00434239
Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia
NaSingle-groupOpen-labelTreatment
Summary
This study is mainly assessing the safety of Revlimid in combination with Ancestim (recombinant human stem cell factor) in patients with symptomatic myelodysplasia. Of those two compounds, Revlimid has been shown to be an active drug in myelodysplasia. Clinical responses will also be assessed.
Timeline
- Start
- 2007-02
- Primary completion
- 2011-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ancestim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | Ancestim | Protein / enzyme biologic | 20 ug/kg | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |